Evidence map›Paper›PMID 35426046›Full record

ArticleSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer2022

A prospective cohort study to evaluate the incidence of febrile neutropenia in patients receiving pegfilgrastim on-body injector versus other options for prophylaxis of febrile neutropenia: breast cancer subgroup analysis.

Reshma L Mahtani, Rajesh Belani, Jeffrey Crawford, David Dale, Lucy DeCosta, Prasad L Gawade, Chanh Huynh, Tatiana Lawrence, Sandra Lewis, William W MacLaughlin and 2 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02178475 (Prospective Observational Study of Febrile Neutropenia), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02178475 completednot on this map

Prospective Observational Study of Febrile Neutropenia (FN) and Pegfilgrastim Primary Prophylaxis in Breast Cancer and Non-Hodgkin's Lymphoma Patients Receiving High (>20%) FN-risk Chemotherapy

TypeobservationalSponsorAmgenRan2014 to 2016Enrolled943ConditionsChemotherapy-induced Febrile Neutropenia
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Reshma L Mahtani *Miami Cancer Institute, Baptist Health South Florida, Miami, FL, USA. rmahtani@baptisthealth.net.ORCID https://orcid.org/0000-0002-7711-8627
Rajesh Belani *Amgen Inc., Thousand Oaks, CA, USA.
Jeffrey CrawfordDuke University School of Medicine, Durham, NC, USA.
David DaleDepartment of Medicine, University of Washington, Seattle, WA, USA.
Lucy DeCostaAmgen Ltd, Uxbridge, UK.
Prasad L GawadeAmgen Inc., Thousand Oaks, CA, USA.
Chanh HuynhCancer Care Associates of York, York, PA, USA.
Tatiana LawrenceAmgen Inc., Thousand Oaks, CA, USA.
Sandra LewisAmgen Inc., Thousand Oaks, CA, USA.
William W MacLaughlinRiverside Health System, Chesapeake, VA, USA.
Mohit NarangUS Oncology Research, Columbia, MD, USA.
Robert RifkinRocky Mountain Cancer Centers, US Oncology Research, Denver, CO, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBreast cancer chemotherapy often carries a high risk of febrile neutropenia (FN); guidelines recommend prophylaxis with granulocyte colony-stimulating factor (G-CSF), such as pegfilgrastim. Neulasta

methodsThis prospective study examined patients with breast cancer who received chemotherapy with a high risk of FN, receiving OBI ("OBI") or other options (other G-CSF or none; "other"). The primary endpoint was FN incidence; secondary endpoints included chemotherapy delivery, adherence (G-CSF in all cycles), compliance (G-CSF day after chemotherapy), and FN incidence in patients receiving curative or palliative treatment.

resultsA total of 1776 patients with breast cancer were enrolled (OBI, n = 1196; other, n = 580). Across all cycles, FN incidence was lower for OBI (4.4% [95% CI, 3.3-5.6%]) than other (7.4% [5.3-9.6%]). For curative treatment, the FN incidence across all cycles was lower for OBI (4.6% [3.4-5.8%]) than for other (7.1% [5.0-9.3%]). For palliative treatment (OBI, n = 33; other, n = 20), 3 patients (15%) in the other and none in the OBI group had FN. After adjusting for baseline covariates, FN incidence remained lower for OBI (4.6% [3.5-6.1%]) versus other (7.8% [5.7-10.5%]). Adherence was higher for OBI (93.8%) than for other G-CSF (69.8%), as was compliance (90.5 and 53.2%, respectively). Chemotherapy dose delays/reductions were similar for OBI (4.7%/32.3%, respectively) and other (4.7%/30.0%) groups.

conclusionPegfilgrastim OBI was associated with a lower FN incidence in patients with breast cancer compared to other options for FN prophylaxis.

trial registrationwww. CLINICALTRIALS: gov , NCT02178475, registered 30 June, 2014.

Indexed as

Breast NeoplasmsFebrile NeutropeniaAntineoplastic Combined Chemotherapy ProtocolsFemaleFilgrastimGranulocyte Colony-Stimulating FactorHumansIncidencePolyethylene GlycolsProspective StudiesRecombinant ProteinsFilgrastimGranulocyte Colony-Stimulating FactorpegfilgrastimPolyethylene GlycolsRecombinant ProteinsBreast cancerChemotherapyComplianceFebrile neutropeniaPegfilgrastim

Identifiers

PMID35426046
PMCPMC9009498

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.